RxDoctor Payments Data

Steven Alsip, MD

Infectious Disease · Mobile, ALNPI 1285657403

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.5% of the total across 126 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by Viiv Healthcare Company at 42.1% of the total. Reporting peaked in 2023 at $759 and has fallen 93.4% since, to $50 in 2024.

$2,359in general payments, 2019–2025

Across 126 payments — averaging $18.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$994
  • Merck$392
  • Insmed, Inc.$194
  • Gilead$184
  • AbbVie$108
  • Theratechnologies Inc.$78
  • plus $411 from 10 others

What the payments were for

  • Food & beverage$2,34799%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,359 in reported general payments places this provider in the 60th percentile of 104 infectious disease providers in Alabama.

See all infectious disease providers in Alabama

Medicare billing

Part B allowed, 2024
$4,297
Medicare patients
28
Services billed
129

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala43$176,528
DovatoDolutegravir Sodium/Lamivudine34$105,726
OzempicSemaglutide11$15,965
Vancomycin Hcl23$3,607
Cefepime Hcl19$1,131
Pravastatin Sodium21$745
Ethambutol Hcl14$711
Doxycycline Hyclate13$408
Levothyroxine Sodium22$260
Atorvastatin Calcium14$223
Metformin Hcl15$213
Rosuvastatin Calcium19$168
Escitalopram Oxalate21$160
Amlodipine Besylate25$149
Hydrochlorothiazide26$135

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy$184$176,52843 claims
Viiv Healthcare CompanyDovato$994$105,72634 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 104 infectious disease providers in Alabama.

Other infectious disease in Mobile

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →